Bifidumbacterin (Bifidumbacterin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBifidobacteria bifidumBifidobacteria bifidum
Similar drugsTo uncover
  • Bifidumbacterin
    suppositories rect. the vagina. 
    PARTNER, CJSC     Russia
  • Bifidumbacterin
    lyophilizate locally inwards 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Bifidumbacterin
    lyophilizate locally inwards 
    VITAFARMA FIRM, CJSC     Russia
  • Bifidumbacterin
    suppositories rect. the vagina. 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Bifidumbacterin
    capsules inwards 
    EKOPOLIS, ZAO     Russia
  • Bifidumbacterin
    lyophilizate locally inwards 
    EKOPOLIS, ZAO     Russia
  • Bifidumbacterin
    lyophilizate inwards locally 
    MICROGEN FGUP Scientific and Production Association     Russia
  • Bifidumbacterin dry
    lyophilizate locally inwards 
    BIOMED them. I.I.Mechnikova, OJSC     Russia
  • Bifidumbacterin forte®
    capsules inwards 
    PARTNER, CJSC     Russia
  • Bifidumbacterin, suppositories
    suppositories rect. the vagina. 
    VITAFARMA FIRM, CJSC     Russia
  • Bifidumbacterin, tablets 1 dose, 5 doses
    pills inwards 
    VITAFARMA FIRM, CJSC     Russia
  • Bifinorm
    lyophilizate locally inwards 
    St. Petersburg Research Institute of Vaccines and Serums and the enterprise for the production of bacterial preparations FSUE FMBA    
    • Dosage form: & nbsplyophilizate for solution for oral administration and topical application
    Composition:

    One dose of the drug contains at least 107 live bifidobacteria. The preparation contains medium of cultivation and components of drying medium: gelatin - from 0,7 to 3,0%, sucrose - from 5 to 10%; milk fat-free - from 15 to 25%.

    Description:

    A crystalline or porous mass of various shades of beige or whitish-gray color, with a specific odor.

    Pharmacotherapeutic group:Eubiotic
    ATX: & nbsp

    A.07.F.A   Antidiarrhoeal preparations of biological origin regulating the balance of intestinal microflora

    Pharmacodynamics:

    The preparation is a microbial mass of living bacteria of an antagonistically active strain Bifidobacterium bifidum 791, lyophilized in a culture medium with the addition of a drying drying medium: sucrose-gelatin-lactic.

    The therapeutic effect of bifidumbacterin determines the living bifidobacteria contained in it, which have antagonistic activity against a wide range pathogenic and conditionally pathogenic microorganisms and thereby normalizing the intestinal microflora.

    The high quantitative level of bifidoflora and its predominance in the microbiocenosis, achieved with the use of bifidumbacterin, normalizes the activity of the gastrointestinal tract,improves metabolic processes, prevents the formation of protracted forms of intestinal diseases, increases the nonspecific resistance of the body.

    Appointment

    Treatment and prevention of dysbacteriosis of various etiologies in children and adults.

    Children (including premature) the drug can be used from the first days of life.

    Indications:

    - Long-term intestinal dysfunction of unknown etiologii;

    - acute intestinal infections (complex treatment of acute dysentery, salmonellosis, escherichiosis, viral diarrhea, etc.);

    - long-term intestinal dysfunctions of staphylococcal etiology, as well as treatment of convalescences after acute intestinal infections with ongoing dysfunction intestines;

    - complex treatment of children (including newborns, prematurity), patients with pneumonia, sepsis and other purulent-infectious diseases for preventing and stopping their bowel function disorders and preventing the development of ulcerative-necrotic enterocolitis;

    - weighed premorbid conditions: children born prematurely or with signs of prematurity receiving antibiotics in the early neonatal period; children whose mothers suffered from severe toxicosis,extragenital diseases, had a long anhydrous period or other pathology of labor, children of mothers with lactostasis, nipple cracking and resuming breastfeeding after recovery from mastitis, weakened children with anemia, hypotrophy, rickets, diathesis and other manifestations of allergy; with pertussis disease, especially if they have any disorders of bowel function;

    - early transfer of infants to artificial feeding with donor milk;

    - acute and chronic inflammatory diseases of the large and small intestine (colitis, enterocolitis), proceeding against a background of microflora disorders with deficiency or absence of bifidoflora;

    - intestinal dysfunctions with intestinal dysbacteriosis, which arose as a result of a prolonged antibacterial, hormoneoMr.aradiation, and other therapy, stressful situations and staying in extreme conditions, as well as with the goal of preventing dysbacteriosis;

    - prevention of mastitis for the treatment of mammary glands of nursing mothers of the "risk" group (in women with a retracted flat nipple, a decrease in its erection, the presence of cracks);

    - treatment and prevention of vaginal dysbiosis and inflammatory diseases of the female sexual sphere (adults): to restore normal microflora after the end fromantimicrobial or antifungal therapy, as a mono drug or in combination with immunomodulating medications:

    - nonspecific vaginitis (colpitis), not gonococcal and trichomonas etiology; vaginal dysbiosis, including bacterial vaginosis (gardneresis); candidiasis of the vagina; complex treatment of urogenital infections and other sexually transmitted diseases (STDs): gonorrhea, urogenital chlamydia and herpes;

    - hormone-dependent colpitis (vaginitis), including senile on the background of hormone replacement therapy;

    - Prenatal preparation of pregnant women at risk for developing inflammatory diseases of the reproductive system with a violation of the purity of the vaginal secretion before III-IV degree for the purpose of prevention and treatment of vaginal dysbiosis.

    Contraindications:

    Not installed.

    Dosing and Administration:

    Bifidumbacterin in intestinal diseases is used inside, and in obstetric-gynecological practice, local intravaginal.The contents of the vial to dissolve boiled water at room temperature at the rate of 5 ml (teaspoon) of water per 1 dose of the drug.

    Dissolve as follows: pour the required amount of water in a glass (according to the number of doses indicated on the vial); open the bottle by removing the cap and stopper; from the glass to transfer a small amount of water into the bottle; after dissolution (the drug dissolves no more than 10 minutes), the contents of the vial should be transferred to the same beaker and moved. One teaspoon of the drug dissolved in this way is 1 dose. Dissolved drug is not subject to storage.

    The required number of doses (respectively, tea spoons) should be taken 20-30 minutes before meals. Breast children can be given the drug immediately before feeding.

    In case of intestinal diseases, the drug is prescribed for 5 children at the reception 2 times a day for children of the first half-year of life, for children of the second half-year and older - 5 doses 3 times a day.

    Newborns of the "risk" group should start using the drug in the maternity department from the first day of life to discharge 2.5 doses per reception 2 times a day.

    With sepsis, pneumonia and other purulent-infectious diseases, children are prescribed 5 doses 3 times a day in combination with conventional methods of treating the underlying disease.

    If this group of children has gastrointestinal dysfunction and the threat of ulcerative-necrotic enterocolitis, the dose of Bifidumbacterin is increased to 20 doses per day.

    In acute and chronic inflammatory diseases of the small and large intestine, colitis and enterocolitis in adults, it is recommended to take 5 doses 2-3 times a day.

    With intestinal diseases, the duration of the course of treatment with bifidumbacterin is determined by the severity of clinical manifestations, the age of the patient and is 2-4 weeks, and in some cases up to 3 months.

    Treatment of the nipple and areola of the puerpera: Dissolve 2 sterile swabs with a dissolved preparation (5 doses) and apply them to the mammary gland for 20-30 minutes before feeding. The course of treatment is 5 days.

    For intravaginal use, apply the sterile swab impregnated with the drug into the vagina and leave for 2-3 hours.

    With inflammatory diseases of the female genitalia and prenatal preparation of the pregnant "risk" group, Bifidumbacterin is prescribed 5-10 doses once a day for 5-8 days under the control of vaginal secretion restoration to I-II degree and disappearance of clinical symptoms of inflammation.

    If necessary, the course of treatment with bifidumbacterin can be repeated.

    With the preventive purpose appoint 5 doses 1-2 times a day for 1-2 weeks.

    Side effects:

    Side effects of the drug are not established.

    Overdose:

    Not installed.

    Interaction:

    The use of bifidumbacterin can be combined with the simultaneous administration of antiviral and immunomodulatory therapy.

    Form release / dosage:Liofilizate for solution for oral administration and topical application.
    Packaging:

    5 doses in a vial.

    10 bottles in a pack of cardboard with instructions for use.

    Storage conditions:

    In accordance with SP 3.3.2.1248-03 at a temperature of 2 to 10 ° C, out of reach of children.

    Transport conditions:

    In accordance with SP 3.3.2.1248-03 at a temperature of 2 to 10 ° C.

    The drug is not suitable for use:

    - if the integrity of the package is violated (cracked bottle);

    - if there is no marking;

    - when changing physical properties (color change);

    - in the presence of extraneous inclusions;

    - expired.

    Shelf life:

    1 year.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-004514/10
    Date of registration:21.05.2010 / 22.10.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:VITAFARMA FIRM, CJSC VITAFARMA FIRM, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspVITAFARMA FIRM, CJSCVITAFARMA FIRM, CJSC
    Information update date: & nbsp14.02.2017
    Illustrated instructions
      Instructions
      Up